Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PYXS - Pyxis Oncology Inc


IEX Last Trade
3.78
0.120   3.175%

Share volume: 300,826
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.66
0.12
3.28%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
2.16%
1 Month
-1.56%
3 Months
1.88%
6 Months
-40.41%
1 Year
79.62%
2 Year
45.21%
Key data
Stock price
$3.78
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.35 - $6.85
52 WEEK CHANGE
$0.63
MARKET CAP 
223.187 M
YIELD 
N/A
SHARES OUTSTANDING 
58.888 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$301,462
AVERAGE 30 VOLUME 
$406,438
Company detail
CEO:
Region: US
Website: pyxisoncology.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.

Recent news